# EDGAR Filing Document

**Accession Number:** 0001766400
**File Stem:** 0001766400-26-000011
**Filing Date:** 2026-2
**Character Count:** 67790
**Document Hash:** 5799cddbb8cfe683be4e64191dc92e53
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001766400-26-000011.hdr.sgml**: 20260225

**ACCESSION NUMBER**: 0001766400-26-000011

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260225

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260225

**DATE AS OF CHANGE**: 20260225

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Pennant Group, Inc.
- **CENTRAL INDEX KEY:** 0001766400
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-HEALTH SERVICES [8000]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38900
- **FILM NUMBER:** 26679066

**BUSINESS ADDRESS:**
- **STREET 1:** 1675 E. RIVERSIDE DRIVE
- **CITY:** EAGLE
- **STATE:** ID
- **ZIP:** 83616
- **BUSINESS PHONE:** (208) 401-1400

**MAIL ADDRESS:**
- **STREET 1:** 1675 E. RIVERSIDE DRIVE
- **CITY:** EAGLE
- **STATE:** ID
- **ZIP:** 83616

?xml version='1.0' encoding='ASCII'? pntg-20260225

    

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): February 25, 2026** 

**The Pennant Group, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38900** | **83-3349931** |
| (State or other jurisdiction<br>of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

---

---

| |
|:---|
| **1675 E Riverside Drive, Suite 150,**<br>**Eagle, ID 83616** |
| (Address of principal executive offices and Zip Code) |

---

Registrant's telephone number, including area code: **(208) 401-1400** 

**Not Applicable**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.001 per share | PNTG | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    

------

**Item 2.02. Results of Operations and Financial Condition.**

On February 25, 2026, The Pennant Group, Inc. (the "Company") issued a press release reporting the financial results of the Company for its fourth quarter ended December 31, 2025. A copy of the press release is attached to this Current Report as Exhibit 99.1.

**Item 7.01. Regulation FD Disclosure.**

The Company will post on its website an updated investor presentation for use at upcoming investor meetings. Please visit investor.pennantgroup.com to access the new presentation materials.

The information furnished pursuant to Item 2.02 and Item 7.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

------

**Item 9.01. Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits.

---

| | |
|:---|:---|
| Exhibit No. | Description |
| <u>[99.1](q42025earningspressrelease.htm)</u> | Press Release of the Company dated February 25, 2026. |
| 104 | Cover Page Interactive Data File – the cover page XBRL tags are embedded within the Inline XBRL document. |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Dated: February 25, 2026 | THE PENNANT GROUP, INC. | THE PENNANT GROUP, INC. |
|  | By: | /s/ LYNETTE B. WALBOM |
|  |  | Lynette B. Walbom |
|  |  | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![pennantlogoa01.jpg](pennantlogoa01.jpg)

**Pennant Reports Fourth Quarter and Fiscal Year 2025 Results**

*Conference Call and Webcast scheduled for tomorrow, February 26, 2026 at 10:00 am MT*

EAGLE, Idaho – February 25, 2026 (GLOBE NEWSWIRE) - The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today announced its operating results, reporting GAAP diluted earnings per share of $0.84 for the full year and $0.24 for the fourth quarter of 2025. Pennant also reported adjusted diluted earnings per share of $1.18 for the full year and $0.34 for the quarter<sup>(1)</sup>.

**<u>Fourth Quarter Highlights</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Total revenue for the full year was $947.7 million, an increase of $252.5 million or 36.3% over the prior year, and for the quarter was $289.3 million, an increase of $100.4 million or 53.2% over the prior year quarter;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Net income for the full year was $29.6 million, an increase of $7.0 million or 31.1% over the prior year and for the fourth quarter was $8.6 million, an increase of $2.9 million or 50.0% over the prior year quarter;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Adjusted net income for the full year was $41.6 million, an increase of $11.6 million or 38.9% over the prior year and for the fourth quarter was $12.2 million, an increase of $3.7 million or 43.1% over the prior year quarter;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Consolidated Adjusted EBITDAR for the full year was $120.9 million, an increase of $25.1 million or 26.2% over the prior year and for the fourth quarter was $35.3 million, an increase of $10.4 million or 41.7% over the prior year quarter;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Consolidated Adjusted EBITDA for the full year was $72.5 million, an increase of $19.2 million or 36.0% over the prior year and for the fourth quarter was $22.4 million, an increase of $8.6 million or 62.5% over the prior year quarter;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Home Health and Hospice Services segment revenue for the full year was $732.7 million, an increase of $213.2 million or 41.0% over the prior year and for the fourth quarter was $233.3 million, an increase of $91.3 million or 64.3% over the prior year quarter;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Home Health and Hospice Services segment adjusted EBITDAR from operations for the full year was $120.8 million, an increase of $33.1 million or 37.8% over prior year and for the fourth quarter was $36.8 million, an increase of $13.6 million or 58.5% over the prior year quarter; and segment adjusted EBITDA from operations the full year was $111.1 million, an increase of $30.5 million or 37.8% over the prior year and for the fourth quarter was $33.7 million, an increase of $12.4 million or 58.2% over the prior year quarter;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Total home health admissions for the the full year were 86,076, an increase of 26,335 or 44.1% over the prior year and for the fourth quarter were 28,941, an increase of 12,982 or 81.3% over the prior year quarter; total Medicare home health admissions for the full year were 34,882, an increase of 10,284 or

------

**Exhibit 99.1**

41.8% over the prior year and for the fourth quarter were 12,082, an increase of 5,639 or 87.5% over the prior year quarter;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Hospice average daily census for the full year was 4,204, an increase of 936 or 28.6% over prior year and for the fourth quarter was 5,060, an increase of 1,615 or 46.9% compared to the prior year quarter;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Senior Living Services segment revenue for the full year was $215.0 million, an increase of $39.2 million or 22.3% over prior year and for the fourth quarter was $56.1 million, an increase of $9.2 million or 19.6% over the prior year quarter; average occupancy for the fourth quarter was 80.6%, an increase of 200 basis points over the prior year quarter, and average monthly revenue per occupied room for the fourth quarter was $5,238 an increase of $277 or 5.6% over the prior year quarter;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Senior Living segment adjusted EBITDAR from operations for the full year was $60.5 million, an increase of $8.9 million or 17.2% over the prior year and for the fourth quarter was $16.0 million, an increase of $2.5 million or 19.0% over the prior year quarter; and segment adjusted EBITDA from Operations for the full year was $21.8 million, an increase of $5.6 million or 34.4% over the prior year and for the fourth quarter was $6.1 million, an increase of $1.9 million or 46.0% over the prior year quarter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

***(1)***  ***See "Reconciliation of GAAP to Non-GAAP Financial Information."***

***(2)***  ***"Same store Senior Living Services" is defined as all senior living communities excluding those transferred to Ensign and new senior living operations acquired in 2024 or 2025.***

**<u>Operating Results</u>**

"2025 was a year of record-breaking performance and growth for Pennant," said Brent Guerisoli, the Company's Chief Executive Officer. "Our operational flywheel continues to gain momentum, even in the midst of accelerative expansion. Our growth wasn't only significant in its magnitude--it was strategic, high-quality investment. We added attractive operations to our footprint and created a foundation for additional expansion in the Southeast. At the same time, we drove strong same-store results and continued to execute in our senior living business."

"We will be focused on integrating our new operations and continuing to instill operational excellence across our businesses in 2026," said John Gochnour, the Company's Chief Operating Officer. "We have completed many acquisitions in our history, and we understand the importance of successful transitions, in terms of employee experience, culture, clinical excellence, and financial results. We saw tremendous momentum across virtually all key growth metrics in 2025, including growth in home health admissions of 44.1% and hospice average daily census of 28.6%, leading to revenue growth of 41.0% and segment Adjusted EBITDA growth of 37.8% year over year. Senior living year-over-year occupancy grew 90 basis points coupled with rate increases of 8.0%, generating revenue growth of 22.3% and Adjusted EBITDA improvement of 34.4%, year over year. Even as we worked diligently to transition many new operations, we delivered record operational and clinical performance in both segments. With seasoned leaders and well-performing operations anchoring our efforts, we are poised to continue this success throughout 2026."

A discussion of the Company's use of Non-GAAP financial measures is set forth below. Reconciliations of net income to EBITDA, adjusted EBITDAR, adjusted EBITDA, and adjusted EBITDA prior to NCI, as well as a reconciliation of GAAP earnings per share, net income to adjusted net earnings per share and adjusted net income, appear in the financial data portion of this release. More complete information is contained in the Company's Form 10-K for the year ended December 31, 2025, which will be filed with the SEC and will be available to be viewed on the Company's website at www.pennantgroup.com.

**<u>2026 Guidance</u>**

Management is providing 2026 annual guidance as follows: total revenue is anticipated to be between $1,133.6 million and $1,171.8 million; full year 2026 adjusted earnings per diluted share is anticipated to be between $1.26

------

**Exhibit 99.1**

and $1.36; full year 2026 adjusted EBITDA is anticipated to be between $88.5 million and $94.1 million; and full year adjusted EBITDA prior to NCI is anticipated to be $94.2 million to $100.0 million.

The Company's updated 2026 annual guidance is based on diluted weighted average shares outstanding of approximately 37.0 million and a 26.0% effective tax rate. The guidance includes among other things, certain costs relating to our transition services agreement with UnitedHealth, reimbursement rate adjustments and no unannounced acquisitions. It excludes net income attributable to noncontrolling interest, the tax-effected costs at start-up operations, share-based compensation, acquisition-related costs, and gain (loss) on disposition of assets and impairments.

Lynette Walbom, the Company's Chief Financial Officer, also stated, "We believe providing updated annual adjusted consolidated EBITDA guidance in addition to updated annual revenue and adjusted earnings per share guidance is helpful to understanding our expectations for our business and operational cash flow. This updated guidance reflects management's expectations based on 2025 performance and current operating conditions as well as the impacts of the transaction with UnitedHealth and Amedisys. Our guidance includes revenue in the range of $191.2 to $200.3 million, adjusted EBITDA in the range of $16.7 to $17.9 million, and adjusted EBITDA prior to NCI of $19.8 to $21.1 million relating to these former UnitedHealth and Amedisys assets."

**<u>Conference Call</u>**

A live webcast will be held tomorrow, February 26, 2026 at 10:00 a.m. Mountain time (12:00 p.m. Eastern time) to discuss Pennant's fourth quarter 2025 financial results. To listen to the webcast, or to view any financial or statistical information required by SEC Regulation G, please visit the Investors Relations section of Pennant's website at https://investor.pennantgroup.com. The webcast will be recorded and will be available for replay via the website.

**<u>About Pennant</u>**

The Pennant Group, Inc. is a holding company of independent operating subsidiaries that provide healthcare services through 172 home health and hospice agencies and 63 senior living communities located throughout Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin and Wyoming. Each of these businesses is operated by a separate, independent operating subsidiary that has its own management, employees and assets. References herein to the consolidated "company" and "its" assets and activities, as well as the use of the terms "we," "us," "its" and similar verbiage, are not meant to imply that The Pennant Group, Inc. has direct operating assets, employees or revenue, or that any of the home health and hospice businesses, senior living communities or the Service Center are operated by the same entity. More information about Pennant is available at www.pennantgroup.com.

***<u>Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995</u>***

*This press release contains, and the related conference call and webcast will include, forward-looking statements that are based on management's current expectations, assumptions and beliefs about its business, financial performance, operating results, the industry in which it operates and other future events. Forward-looking statements can often be identified by words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "could," "potential," "continue," "ongoing," similar expressions, and variations or negatives of these words. These forward-looking statements include, but are not limited to, statements regarding growth prospects, future operating and financial performance, and acquisition activities. They are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to materially and adversely differ from those expressed in any forward-looking statement.* 

*These risks and uncertainties relate to the company's business, its industry and its common stock and include: reduced prices and reimbursement rates for its services; its ability to acquire, develop, manage or improve operations, its ability to manage its increasing borrowing costs as it incurs additional indebtedness to fund the acquisition and development of operations; its ability to access capital on a cost-effective basis to continue to* 

------

**Exhibit 99.1**

*successfully implement its growth strategy; its operating margins and profitability could suffer if it is unable to grow and manage effectively its increasing number of operations; competition from other companies in the acquisition, development and operation of facilities; its ability to defend claims and lawsuits, including professional liability claims alleging that our services resulted in personal injury, and other regulatory-related claims; and the application of existing or proposed government regulations, or the adoption of new laws and regulations, that could limit its business operations, require it to incur significant expenditures or limit its ability to relocate its operations if necessary. Readers should not place undue reliance on any forward-looking statements and are encouraged to review the company's periodic filings with the Securities and Exchange Commission, including its Form 10-Q and/or 10-K, for a more complete discussion of the risks and other factors that could affect Pennant's business, prospects and any forward-looking statements. Except as required by the federal securities laws, Pennant does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changing circumstances or any other reason after the date of this press release.*

**<u>Contact Information</u>**

Investor Relations

The Pennant Group, Inc.

(208) 401-1400

ir@pennantgroup.com

SOURCE: The Pennant Group, Inc.

------

**Exhibit 99.1**

**THE PENNANT GROUP, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF INCOME**

**(unaudited, in thousands, except for per-share amounts)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2025** | **2024** |
| Revenue | $289323 | $188892 | $947705 | $695240 |
| Expense |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Cost of services | 237053 | 152673 | 768503 | 558449 |
| &nbsp;&nbsp;&nbsp;Rent—cost of services | 12997 | 11215 | 48700 | 43029 |
| &nbsp;&nbsp;&nbsp;General and administrative expense | 19344 | 13872 | 71077 | 50209 |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 2359 | 1827 | 8538 | 6119 |
| &nbsp;&nbsp;&nbsp;(Gain) loss on disposition of property and equipment, net | 100 | 69 | (999) | (682) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total expenses | 271853 | 179656 | 895819 | 657124 |
| Income from operations | 17470 | 9236 | 51886 | 38116 |
| Other (expense) income, net: |  |  |  |  |
| &nbsp;&nbsp;Other income | 54 | 15 | 422 | 207 |
| &nbsp;&nbsp;Interest expense, net | (3253) | (650) | (6678) | (6956) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other expense, net | (3199) | (635) | (6256) | (6749) |
| Income before provision for income taxes | 14271 | 8601 | 45630 | 31367 |
| Provision for income taxes | 3896 | 2071 | 11866 | 7028 |
| Net income | 10375 | 6530 | 33764 | 24339 |
| Less: Net income attributable to noncontrolling interest | 1738 | 772 | 4186 | 1780 |
| Net income attributable to The Pennant Group, Inc. | $8637 | $5758 | $29578 | $22559 |
| Earnings per share: |  |  |  |  |
| &nbsp;&nbsp;Basic | $0.25 | $0.17 | $0.86 | $0.72 |
| &nbsp;&nbsp;Diluted | $0.24 | $0.16 | $0.84 | $0.70 |
| Weighted average common shares outstanding: |  |  |  |  |
| &nbsp;&nbsp;Basic | 34652 | 34269 | 34563 | 31191 |
| &nbsp;&nbsp;Diluted | 35442 | 35333 | 35316 | 32000 |

---

------

**Exhibit 99.1**

**THE PENNANT GROUP, INC.**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(in thousands, except par value)**

---

| | | |
|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2024** |
| **Assets** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;Cash | $17024 | $24246 |
| &nbsp;&nbsp;Accounts receivable—less allowance for doubtful accounts of $681 and $232, at December 31, 2025 and December 31, 2024 respectively | 123109 | 81302 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 27273 | 17308 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 167406 | 122856 |
| Property and equipment, net | 60984 | 43296 |
| Operating lease right-of-use assets | 275947 | 270586 |
| Deferred tax assets, net | 478 |  |
| Restricted and other assets | 26676 | 17477 |
| Goodwill | 237246 | 129124 |
| Other indefinite-lived intangibles | 199442 | 96182 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $968179 | $679521 |
| **Liabilities and equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | $25171 | $18737 |
| &nbsp;&nbsp;&nbsp;Accrued wages and related liabilities | 65229 | 43106 |
| &nbsp;&nbsp;&nbsp;Operating lease liabilities—current | 25013 | 19671 |
| &nbsp;&nbsp;&nbsp;Current maturities of long-term debt | 5000 |  |
| &nbsp;&nbsp;&nbsp;Other accrued liabilities | 26851 | 20186 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 147264 | 101700 |
| Long-term operating lease liabilities—less current portion | 254311 | 253420 |
| Deferred tax liabilities, net | 150 | 1861 |
| Other long-term liabilities | 23365 | 10575 |
| Long-term debt | 168837 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 593927 | 367556 |
| Commitments and contingencies |  |  |
| Equity: |  |  |
| &nbsp;&nbsp;Common stock, $0.001 par value; 100,000 shares authorized; 34,878 and 34,626 shares issued and outstanding at December 31, 2025, respectively; and 34,670 and 34,373 shares issued and outstanding at December 31, 2024, respectively  | 35 | 35 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 245833 | 236091 |
| &nbsp;&nbsp;&nbsp;Retained earnings | 86800 | 57222 |
| &nbsp;&nbsp;Treasury stock, at cost, 3 shares at December 31, 2025 and December 31, 2024 | (65) | (65) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total The Pennant Group, Inc. stockholders' equity | 332603 | 293283 |
| &nbsp;&nbsp;&nbsp;Noncontrolling interest | 41649 | 18682 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total equity | 374252 | 311965 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and equity | $968179 | $679521 |

---

------

**Exhibit 99.1**

**THE PENNANT GROUP, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(in thousands)**

The following table presents selected data from our condensed consolidated statements of cash flows for the periods presented:

---

| | | |
|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** |
| Net cash provided by operating activities | $48294 | $39298 |
| Net cash used in investing activities | (227971) | (70684) |
| Net cash provided by financing activities | 172455 | 49573 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net increase (decrease) in cash | (7222) | 18187 |
| Cash beginning of period | 24246 | 6059 |
| Cash end of period | $17024 | $24246 |

---

------

**Exhibit 99.1**

**THE PENNANT GROUP, INC.**

**REVENUE BY SEGMENT**

**(unaudited, dollars in thousands)**

The following table sets forth our total revenue by segment and as a percentage of total revenue for the periods indicated:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** |
| | **2025** | **2025** | **2024** | **2024** |
| | **Revenue Dollars** | **Revenue Percentage** | **Revenue Dollars** | **Revenue Percentage** |
| Home health and hospice services |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Home health | $116432 | 40.2% | $66766 | 35.3% |
| &nbsp;&nbsp;&nbsp;Hospice | 97061 | 33.5 | 63391 | 33.6 |
| &nbsp;&nbsp;Home care and other<sup>(a)</sup> | 19779 | 6.9 | 11864 | 6.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total home health and hospice services | 233272 | 80.6 | 142021 | 75.2 |
| Senior living services | 56051 | 19.4 | 46871 | 24.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total revenue | $289323 | 100.0% | $188892 | 100.0% |

---

(a) Home care and other revenue is included with home health revenue in other disclosures in this press release.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2025** | **2024** | **2024** |
| | **Revenue Dollars** | **Revenue Percentage** | **Revenue Dollars** | **Revenue Percentage** |
| Home health and hospice services |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Home health | $351240 | 37.1% | $239539 | 34.5% |
| &nbsp;&nbsp;&nbsp;Hospice | 317801 | 33.5 | 240102 | 34.5 |
| &nbsp;&nbsp;Home care and other<sup>(a)</sup> | 63686 | 6.7 | 39843 | 5.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total home health and hospice services | 732727 | 77.3 | 519484 | 74.7 |
| Senior living services | 214978 | 22.7 | 175756 | 25.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total revenue | $947705 | 100.0% | $695240 | 100.0% |

---

(a) Home care and other revenue is included with home health revenue in other disclosures in this press release.

------

**Exhibit 99.1**

**THE PENNANT GROUP, INC.**

**SELECT PERFORMANCE INDICATORS**

**(unaudited, total revenue dollars in thousands)**

The following table summarizes our overall home health and hospice performance indicators for the each of the dates or periods indicated:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | | |
| | **2025** | **2024** | **Change** | **% Change** |
| **Total agency results:** |  |  |  |  |
| &nbsp;&nbsp;Home health and hospice revenue | $233272 | $142021 | $91251 | 64.3% |
| Home health services: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total home health admissions | 28941 | 15959 | 12982 | 81.3% |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Medicare home health admissions | 12082 | 6443 | 5639 | 87.5% |
| &nbsp;&nbsp;&nbsp;&nbsp;Average Medicare revenue per 60-day completed episode<sup>(a)</sup> | $3755 | $3727 | $28 | 0.8% |
| Hospice services: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total hospice admissions | 4423 | 3090 | 1333 | 43.1% |
| &nbsp;&nbsp;&nbsp;&nbsp;Average daily census | 5060 | 3445 | 1615 | 46.9% |
| &nbsp;&nbsp;&nbsp;&nbsp;Hospice Medicare revenue per day | $192 | $186 | $6 | 3.2% |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | | |
| | **2025** | **2024** | **Change** | **% Change** |
| **Same agency**<sup>(b)</sup> **results:**  |  |  |  |  |
| &nbsp;&nbsp;Home health and hospice revenue | $138177 | $121557 | $16620 | 13.7% |
| Home health services: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total home health admissions | 13655 | 13098 | 557 | 4.3% |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Medicare home health admissions | 5710 | 5277 | 433 | 8.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;Average Medicare revenue per 60-day completed episode<sup>(a)</sup> | $3654 | $3525 | $129 | 3.7% |
| Hospice services: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total hospice admissions | 3165 | 2970 | 195 | 6.6% |
| &nbsp;&nbsp;&nbsp;&nbsp;Average daily census | 3574 | 3296 | 278 | 8.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;Hospice Medicare revenue per day | $198 | $187 | $11 | 5.9% |

---

------

**Exhibit 99.1**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | | |
| | **2025** | **2024** | **Change** | **% Change** |
| **Total agency results:** |  |  |  |  |
| Home health and hospice revenue | $732727 | $519484 | $213243 | 41.0% |
| Home health services: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total home health admissions | 86076 | 59741 | 26335 | 44.1% |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Medicare home health admissions | 34882 | 24598 | 10284 | 41.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;Average Medicare revenue per 60-day completed episode<sup>(a)</sup> | $3755 | $3628 | $127 | 3.5% |
| Hospice services: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total hospice admissions | 15189 | 12208 | 2981 | 24.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;Average daily census | 4204 | 3268 | 936 | 28.6% |
| &nbsp;&nbsp;&nbsp;&nbsp;Hospice Medicare revenue per day | $192 | $183 | $9 | 4.9% |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | | |
| | **2025** | **2024** | **Change** | **% Change** |
| **Same agency**<sup>(b)</sup> **results:**  |  |  |  |  |
| Home health and hospice revenue | $517976 | $465108 | $52868 | 11.4% |
| Home health services: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total home health admissions | 54460 | 50746 | 3714 | 7.3% |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Medicare home health admissions | 22272 | 21146 | 1126 | 5.3% |
| &nbsp;&nbsp;&nbsp;&nbsp;Average Medicare revenue per 60-day completed episode<sup>(a)</sup> | $3617 | $3495 | $122 | 3.5% |
| Hospice services: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total hospice admissions | 12430 | 11677 | 753 | 6.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;Average daily census | 3438 | 3189 | 249 | 7.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;Hospice Medicare revenue per day | $192 | $186 | $6 | 3.2% |

---

(a) The year to date average for Medicare revenue per 60-day completed episode includes post period claim adjustments for prior periods.

(b) Same agency results represent all agencies purchased or licensed prior to January 1, 2024.

The following table summarizes our senior living performance indicators for the periods indicated:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | | |
| | **2025** | **2024** | **Change** | **% Change** |
| **Total senior living results:** |  |  |  |  |
| Senior living revenue | $56051 | $46871 | $9180 | 19.6% |
| Occupancy | 80.6% | 78.6% | 2.0% |  |
| Average monthly revenue per occupied unit | $5238 | $4961 | $277 | 5.6% |

---

------

**Exhibit 99.1**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | | |
| | **2025** | **2024** | **Change** | **% Change** |
| **Same store senior living**<sup>(a)</sup> **results:**  |  |  |  |  |
| Senior living revenue | $46646 | $43041 | $3605 | 8.4% |
| Occupancy | 82.1% | 79.6% | 2.5% |  |
| Average monthly revenue per occupied unit | $5181 | $4905 | $276 | 5.6% |

---

The following table summarizes our senior living performance indicators for the periods indicated:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | | |
| | **2025** | **2024** | **Change** | **% Change** |
| **Total senior living results:** |  |  |  |  |
| Senior living revenue | $214978 | $175756 | $39222 | 22.3% |
| Occupancy | 79.7% | 78.8% | 0.9% |  |
| Average monthly revenue per occupied unit | $5195 | $4811 | $384 | 8.0% |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | | |
| | **2025** | **2024** | **Change** | **% Change** |
| **Same store senior living**<sup>(a)</sup> **results:**  |  |  |  |  |
| Senior living revenue | $180576 | $165926 | $14650 | 8.8% |
| Occupancy | 80.8% | 79.7% | 1.1% |  |
| Average monthly revenue per occupied unit | $5136 | $4769 | $367 | 7.7% |

---

(a) Same store senior living results represent all senior living communities purchased or licensed prior to January 1, 2024, excluding affiliate memory care units in transition.

------

**Exhibit 99.1**

**THE PENNANT GROUP, INC.**

**REVENUE BY PAYOR SOURCE**

**(unaudited, dollars in thousands)**

The following table presents our total revenue by payor source as a percentage of total revenue for the periods indicated:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** |
| | **2025** | **2025** | **2024** | **2024** |
| | **Revenue Dollars** | **Revenue Percentage** | **Revenue Dollars** | **Revenue Percentage** |
| **Revenue:** |  |  |  |  |
| Medicare | $144522 | 50.0% | $90116 | 47.7% |
| Medicaid | 34426 | 11.9 | 25318 | 13.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Subtotal | 178948 | 61.9 | 115434 | 61.1 |
| Managed care | 48114 | 16.6 | 26613 | 14.1 |
| Private and other<sup>(a)</sup> | 62261 | 21.5 | 46845 | 24.8 |
| &nbsp;&nbsp;&nbsp;Total revenue | $289323 | 100.0% | $188892 | 100.0% |

---

(a) Private and other payors includes revenue from all payors generated in the Company's home care operations and management services agreement.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2025** | **2024** | **2024** |
| | **Revenue Dollars** | **Revenue Percentage** | **Revenue Dollars** | **Revenue Percentage** |
| **Revenue:** |  |  |  |  |
| Medicare | $458299 | 48.4% | $335862 | 48.3% |
| Medicaid | 124028 | 13.1 | 91704 | 13.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Subtotal | 582327 | 61.5 | 427566 | 61.5 |
| Managed care | 142382 | 15.0 | 92697 | 13.3 |
| Private and other<sup>(a)</sup> | 222996 | 23.5 | 174977 | 25.2 |
| &nbsp;&nbsp;&nbsp;Total revenue | $947705 | 100.0% | $695240 | 100.0% |

---

(a) Private and other payors includes revenue from all payors generated in the Company's home care operations and management services agreement.

------

**Exhibit 99.1**

**THE PENNANT GROUP, INC.**

**RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION**

**(unaudited, in thousands, except per share data)**

The following table reconciles net income to Non-GAAP net income for the periods presented:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2025** | **2024** |
| Net income attributable to The Pennant Group, Inc. | $8637 | $5758 | $29578 | $22559 |
| **Non-GAAP adjustments** |  |  |  |  |
| Costs at start-up operations<sup>(a)</sup> | 374 | 229 | 515 | 473 |
| Share-based compensation expense<sup>(b)</sup> | 2177 | 2425 | 9036 | 8242 |
| Acquisition related costs<sup>(c)</sup> | 1102 | 282 | 6587 | 1278 |
| Interest expense - write off deferred financing fees<sup>(e)</sup> |  |  |  | 428 |
| Activities associated with transitioning operations<sup>(d)</sup> | 151 | 68 | (660) | (350) |
| Transition services costs<sup>(e)</sup> | 503 |  | 503 |  |
| Unusual, non-recurring or redundant charges<sup>(f)</sup> | 12 | 458 | 113 | 1004 |
| Provision for income taxes on Non-GAAP adjustments<sup>(g)</sup> | (800) | (726) | (4059) | (3668) |
| **Non-GAAP net income** | $12156 | $8494 | $41613 | $29966 |
| **Dilutive Earnings Per Share As Reported** |  |  |  |  |
| Net Income | $0.24 | $0.16 | $0.84 | $0.70 |
| Average number of shares outstanding | 35442 | 35333 | 35316 | 32000 |
| **Adjusted Diluted Earnings Per Share** |  |  |  |  |
| Net Income | $0.34 | $0.24 | $1.18 | $0.94 |
| Average number of shares outstanding | 35442 | 35333 | 35316 | 32000 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| (a) | Represents results related to start-up operations. | Represents results related to start-up operations. | Represents results related to start-up operations. | Represents results related to start-up operations. | Represents results related to start-up operations. |
|  |  | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
|  |  | **2025** | **2024** | **2025** | **2024** |
|  | Revenue | $(1364) | $(172) | $(6235) | $(5128) |
|  | Cost of services | 1633 | 381 | 6417 | 5265 |
|  | Rent | 15 | 18 | 56 | 324 |
|  | Depreciation & amortization | 90 | 2 | 277 | 12 |
|  | Total Non-GAAP adjustment | $374 | $229 | $515 | $473 |
| (b) | Represents share-based compensation expense incurred for the periods presented. | Represents share-based compensation expense incurred for the periods presented. | Represents share-based compensation expense incurred for the periods presented. | Represents share-based compensation expense incurred for the periods presented. | Represents share-based compensation expense incurred for the periods presented. |
|  |  | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
|  |  | **2025** | **2024** | **2025** | **2024** |
|  | Cost of services | $1402 | $1039 | $5260 | $3853 |
|  | General and administrative | 775 | 1386 | 3776 | 4389 |
|  | Total Non-GAAP adjustment | $2177 | $2425 | $9036 | $8242 |
| (c) | Represents costs incurred to acquire an operation that are not capitalizable. | Represents costs incurred to acquire an operation that are not capitalizable. | Represents costs incurred to acquire an operation that are not capitalizable. | Represents costs incurred to acquire an operation that are not capitalizable. | Represents costs incurred to acquire an operation that are not capitalizable. |

---

------

**Exhibit 99.1**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| (d) | During 2024 and 2025, an affiliate of the Company held its memory care units in transition and is converting the facility into an assisted living community. We received insurance proceeds related to the property in 2024 and 2025 which were recorded in gain on disposition of property and equipment, net on the consolidated statements of income. | During 2024 and 2025, an affiliate of the Company held its memory care units in transition and is converting the facility into an assisted living community. We received insurance proceeds related to the property in 2024 and 2025 which were recorded in gain on disposition of property and equipment, net on the consolidated statements of income. | During 2024 and 2025, an affiliate of the Company held its memory care units in transition and is converting the facility into an assisted living community. We received insurance proceeds related to the property in 2024 and 2025 which were recorded in gain on disposition of property and equipment, net on the consolidated statements of income. | During 2024 and 2025, an affiliate of the Company held its memory care units in transition and is converting the facility into an assisted living community. We received insurance proceeds related to the property in 2024 and 2025 which were recorded in gain on disposition of property and equipment, net on the consolidated statements of income. | During 2024 and 2025, an affiliate of the Company held its memory care units in transition and is converting the facility into an assisted living community. We received insurance proceeds related to the property in 2024 and 2025 which were recorded in gain on disposition of property and equipment, net on the consolidated statements of income. | During 2024 and 2025, an affiliate of the Company held its memory care units in transition and is converting the facility into an assisted living community. We received insurance proceeds related to the property in 2024 and 2025 which were recorded in gain on disposition of property and equipment, net on the consolidated statements of income. | During 2024 and 2025, an affiliate of the Company held its memory care units in transition and is converting the facility into an assisted living community. We received insurance proceeds related to the property in 2024 and 2025 which were recorded in gain on disposition of property and equipment, net on the consolidated statements of income. | During 2024 and 2025, an affiliate of the Company held its memory care units in transition and is converting the facility into an assisted living community. We received insurance proceeds related to the property in 2024 and 2025 which were recorded in gain on disposition of property and equipment, net on the consolidated statements of income. | During 2024 and 2025, an affiliate of the Company held its memory care units in transition and is converting the facility into an assisted living community. We received insurance proceeds related to the property in 2024 and 2025 which were recorded in gain on disposition of property and equipment, net on the consolidated statements of income. |
|  |  | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
|  |  | **2025** | **2025** | **2024** | **2024** | **2025** | **2025** | **2024** | **2024** |
|  | Revenue | $|  | $|  | $|  | $| (1) |
|  | Cost of services | 96 | 96 | 13 | 13 | 181 | 181 | (569) | (569) |
|  | Rent | 52 | 52 | 52 | 52 | 209 | 209 | 209 | 209 |
|  | Depreciation | 3 | 3 | 3 | 3 | 11 | 11 | 11 | 11 |
|  | Gain on disposition of property and equipment, net |  |  |  |  | (1061) | (1061) |  |  |
|  | Total Non-GAAP adjustment | $| 151 | $| 68 | $| (660) | $| (350) |
| (e) | Costs identified as redundant or non-recurring incurred by the Company as a result of the Transition Services Agreement between the Company and UnitedHealth entered into as part of the acquisition agreement. All amounts are included in Cost of services. Fees incurred under the transition services agreement were $3,001 for the year ended December 31, 2025. | Costs identified as redundant or non-recurring incurred by the Company as a result of the Transition Services Agreement between the Company and UnitedHealth entered into as part of the acquisition agreement. All amounts are included in Cost of services. Fees incurred under the transition services agreement were $3,001 for the year ended December 31, 2025. | Costs identified as redundant or non-recurring incurred by the Company as a result of the Transition Services Agreement between the Company and UnitedHealth entered into as part of the acquisition agreement. All amounts are included in Cost of services. Fees incurred under the transition services agreement were $3,001 for the year ended December 31, 2025. | Costs identified as redundant or non-recurring incurred by the Company as a result of the Transition Services Agreement between the Company and UnitedHealth entered into as part of the acquisition agreement. All amounts are included in Cost of services. Fees incurred under the transition services agreement were $3,001 for the year ended December 31, 2025. | Costs identified as redundant or non-recurring incurred by the Company as a result of the Transition Services Agreement between the Company and UnitedHealth entered into as part of the acquisition agreement. All amounts are included in Cost of services. Fees incurred under the transition services agreement were $3,001 for the year ended December 31, 2025. | Costs identified as redundant or non-recurring incurred by the Company as a result of the Transition Services Agreement between the Company and UnitedHealth entered into as part of the acquisition agreement. All amounts are included in Cost of services. Fees incurred under the transition services agreement were $3,001 for the year ended December 31, 2025. | Costs identified as redundant or non-recurring incurred by the Company as a result of the Transition Services Agreement between the Company and UnitedHealth entered into as part of the acquisition agreement. All amounts are included in Cost of services. Fees incurred under the transition services agreement were $3,001 for the year ended December 31, 2025. | Costs identified as redundant or non-recurring incurred by the Company as a result of the Transition Services Agreement between the Company and UnitedHealth entered into as part of the acquisition agreement. All amounts are included in Cost of services. Fees incurred under the transition services agreement were $3,001 for the year ended December 31, 2025. | Costs identified as redundant or non-recurring incurred by the Company as a result of the Transition Services Agreement between the Company and UnitedHealth entered into as part of the acquisition agreement. All amounts are included in Cost of services. Fees incurred under the transition services agreement were $3,001 for the year ended December 31, 2025. |
| (f) | Represents unusual, non-recurring, or redundant charges for legal services, implementation costs, integration costs, and consulting fees in general and administrative and cost of services expenses. | Represents unusual, non-recurring, or redundant charges for legal services, implementation costs, integration costs, and consulting fees in general and administrative and cost of services expenses. | Represents unusual, non-recurring, or redundant charges for legal services, implementation costs, integration costs, and consulting fees in general and administrative and cost of services expenses. | Represents unusual, non-recurring, or redundant charges for legal services, implementation costs, integration costs, and consulting fees in general and administrative and cost of services expenses. | Represents unusual, non-recurring, or redundant charges for legal services, implementation costs, integration costs, and consulting fees in general and administrative and cost of services expenses. | Represents unusual, non-recurring, or redundant charges for legal services, implementation costs, integration costs, and consulting fees in general and administrative and cost of services expenses. | Represents unusual, non-recurring, or redundant charges for legal services, implementation costs, integration costs, and consulting fees in general and administrative and cost of services expenses. | Represents unusual, non-recurring, or redundant charges for legal services, implementation costs, integration costs, and consulting fees in general and administrative and cost of services expenses. | Represents unusual, non-recurring, or redundant charges for legal services, implementation costs, integration costs, and consulting fees in general and administrative and cost of services expenses. |
| (g) | Represents an adjustment to the provision for income tax to the year-to-date effective tax rate of 25.8% and 25.2% for the year ended December 31, 2025 and 2024, respectively. This rate excludes the tax benefit of share-based payment awards. | Represents an adjustment to the provision for income tax to the year-to-date effective tax rate of 25.8% and 25.2% for the year ended December 31, 2025 and 2024, respectively. This rate excludes the tax benefit of share-based payment awards. | Represents an adjustment to the provision for income tax to the year-to-date effective tax rate of 25.8% and 25.2% for the year ended December 31, 2025 and 2024, respectively. This rate excludes the tax benefit of share-based payment awards. | Represents an adjustment to the provision for income tax to the year-to-date effective tax rate of 25.8% and 25.2% for the year ended December 31, 2025 and 2024, respectively. This rate excludes the tax benefit of share-based payment awards. | Represents an adjustment to the provision for income tax to the year-to-date effective tax rate of 25.8% and 25.2% for the year ended December 31, 2025 and 2024, respectively. This rate excludes the tax benefit of share-based payment awards. | Represents an adjustment to the provision for income tax to the year-to-date effective tax rate of 25.8% and 25.2% for the year ended December 31, 2025 and 2024, respectively. This rate excludes the tax benefit of share-based payment awards. | Represents an adjustment to the provision for income tax to the year-to-date effective tax rate of 25.8% and 25.2% for the year ended December 31, 2025 and 2024, respectively. This rate excludes the tax benefit of share-based payment awards. | Represents an adjustment to the provision for income tax to the year-to-date effective tax rate of 25.8% and 25.2% for the year ended December 31, 2025 and 2024, respectively. This rate excludes the tax benefit of share-based payment awards. | Represents an adjustment to the provision for income tax to the year-to-date effective tax rate of 25.8% and 25.2% for the year ended December 31, 2025 and 2024, respectively. This rate excludes the tax benefit of share-based payment awards. |

---

The table below reconciles Consolidated net income to the Consolidated Non-GAAP financial measure, Consolidated Adjusted EBITDA, and to the Non-GAAP valuation measure, Consolidated Adjusted EBITDAR, for the periods presented:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2025** | **2024** |
| Consolidated net income | $10375 | $6530 | $33764 | $24339 |
| Less: Net income attributable to noncontrolling interest | 1738 | 772 | 4186 | 1780 |
| Add: Provision for income taxes | 3896 | 2071 | 11866 | 7028 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net interest expense | 3253 | 650 | 6678 | 6956 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 2359 | 1827 | 8538 | 6119 |
| &nbsp;&nbsp;&nbsp;&nbsp;Consolidated EBITDA | 18145 | 10306 | 56660 | 42662 |
| Adjustments to Consolidated EBITDA |  |  |  |  |
| Add: Start-up operations<sup>(a)</sup> | 269 | 209 | 182 | 137 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation expense<sup>(b)</sup> | 2177 | 2425 | 9036 | 8242 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acquisition related costs<sup>(c)</sup> | 1102 | 282 | 6587 | 1278 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Activities associated with transitioning operations<sup>(d)</sup> | 96 | 13 | (880) | (570) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transition services costs<sup>(e)</sup> | 503 |  | 503 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unusual, non-recurring, or redundant charges<sup>(f)</sup> | 12 | 458 | 113 | 1004 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rent related to items (a) and (d) above | 67 | 70 | 265 | 533 |
| &nbsp;&nbsp;&nbsp;&nbsp;Consolidated Adjusted EBITDA | 22371 | 13763 | 72466 | 53286 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rent—cost of services | 12997 | 11215 | 48700 | 43029 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rent related to items (a) and (d) above | (67) | (70) | (265) | (533) |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted rent—cost of services | 12930 | 11145 | 48435 | 42496 |
| &nbsp;&nbsp;&nbsp;&nbsp;Consolidated Adjusted EBITDAR<sup>(g)</sup> | $35301 |  | $120901 |  |

---

------

**Exhibit 99.1**

(a) Represents results related to start-up operations. This amount excludes rent and depreciation and amortization expense related to such operations.

(b) Share-based compensation expense and related payroll taxes incurred. Share-based compensation expense and related payroll taxes are included in cost of services and general and administrative expense.

(c) Non-capitalizable costs associated with acquisitions and write-offs for amounts in dispute with the prior owners of certain acquired operations.

(d) During 2024 and 2025, an affiliate of the Company held its memory care units in transition and is converting the facility into an assisted living community. We received insurance proceeds related to the property in 2024 and 2025 which were recorded in gain on disposition of property and equipment, net on the consolidated statements of income.

(e) Costs identified as redundant or non-recurring incurred by the Company as a result of the Transition Services Agreement between the Company and UnitedHealth entered into as part of the acquisition agreement. All amounts are included in Cost of services. Fees incurred under the transition services agreement were $3,001 for the year ended December 31, 2025.

(f) Represents unusual, non-recurring, or redundant charges for legal services, implementation costs, integration costs, and consulting fees in general and administrative and cost of services expenses.

(g) This measure is a valuation measure and is displayed thusly, it is not a performance measure as it excludes rent expense, which is a normal and recurring operating expense and, as such, does not reflect our cash requirements for leasing commitments. Our presentation of Consolidated Adjusted EBITDAR should not be construed as a financial performance measure.

The table below reconciles Consolidated net income attributable to The Pennant Group, Inc. to the Consolidated Non-GAAP financial measures, Consolidated Adjusted EBITDA and Consolidated Adjusted EBITDA prior to NCI, for the periods presented:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2025** | **2024** |
| Net income attributable to The Pennant Group, Inc. | $8637 | $5758 | $29578 | $22559 |
| Add: Provision for income taxes | 3896 | 2071 | 11866 | 7028 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net interest expense | 3253 | 650 | 6678 | 6956 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 2359 | 1827 | 8538 | 6119 |
| &nbsp;&nbsp;&nbsp;&nbsp;Consolidated EBITDA | 18145 | 10306 | 56660 | 42662 |
| Adjustments to Consolidated EBITDA |  |  |  |  |
| Add: Start-up operations<sup>(a)</sup> | 269 | 209 | 182 | 137 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation expense<sup>(b)</sup> | 2177 | 2425 | 9036 | 8242 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acquisition related costs<sup>(c)</sup> | 1102 | 282 | 6587 | 1278 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Activities associated with transitioning operations<sup>(d)</sup> | 96 | 13 | (880) | (570) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transition services costs<sup>(e)</sup> | 503 |  | 503 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unusual, non-recurring, or redundant charges<sup>(f)</sup> | 12 | 458 | 113 | 1004 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rent related to items (a) and (d) above | 67 | 70 | 265 | 533 |
| &nbsp;&nbsp;&nbsp;&nbsp;Consolidated Adjusted EBITDA | 22371 | 13763 | 72466 | 53286 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Add: Net Income attributable to noncontrolling interest ("NCI") | 1738 | 772 | 4186 | 1780 |
| &nbsp;&nbsp;&nbsp;&nbsp;Consolidated Adjusted EBITDA prior to NCI | $24109 | $14535 | $76652 | $55066 |

---

(a) Represents results related to start-up operations. This amount excludes rent and depreciation and amortization expense related to such operations.

(b) Share-based compensation expense and related payroll taxes incurred. Share-based compensation expense and related payroll taxes are included in cost of services and general and administrative expense.

(c) Non-capitalizable costs associated with acquisitions and write-offs for amounts in dispute with the prior owners of certain acquired operations.

(d) During 2024 and 2025, an affiliate of the Company held its memory care units in transition and is converting the facility into an assisted living community. We received insurance proceeds related to the property in 2024 and 2025 which were recorded in gain on disposition of property and equipment, net on the consolidated statements of income.

(e) Costs identified as redundant or non-recurring incurred by the Company as a result of the Transition Services Agreement between the Company and UnitedHealth entered into as part of the acquisition agreement. All amounts are included in Cost of services. Fees incurred under the transition services agreement were $3,001 for the year ended December 31, 2025.

(f) Represents unusual, non-recurring, or redundant charges for legal services, implementation costs, integration costs, and consulting fees in general and administrative and cost of services expenses.

------

**Exhibit 99.1**

The following tables present certain financial information regarding our reportable segments. General and administrative expenses are not allocated to the reportable segments:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Home Health and Hospice Services** | **Senior Living Services** | **All Other** | **Total** |
| **Three Months Ended December 31, 2025** | | | | |
| Revenue | $233156 | $54802 | $1365 | $289323 |
| &nbsp;&nbsp;Segment Cost of Services | 196352 | 38822 |  |  |
| Segment Adjusted EBITDAR from Operations | $36804 | $15980 |  | $52784 |
| **Three Months Ended December 31, 2024** |  |  |  |  |
| Revenue | $141849 | $46871 | $172 | $188892 |
| &nbsp;&nbsp;Segment Cost of Services | 118628 | 33437 |  |  |
| Segment Adjusted EBITDAR from Operations | $23221 | $13434 |  | $36655 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Home Health and Hospice Services** | **Senior Living Services** | **All Other** | **Total** |
| **Year Ended December 31, 2025** | | | | |
| Segment Revenue | $731392 | $210078 | $6235 | $947705 |
| &nbsp;&nbsp;&nbsp;&nbsp;Segment Cost of Services | 610561 | 149553 |  |  |
| Segment Adjusted EBITDAR from Operations | $120831 | $60525 |  | $181356 |
| **Year Ended December 31, 2024** |  |  |  |  |
| Segment Revenue | $515344 | $174767 | $5129 | $695240 |
| &nbsp;&nbsp;Segment Cost of Services | 427635 | 123107 |  |  |
| Segment Adjusted EBITDAR from Operations | $87709 | $51660 |  | $139369 |

---

------

**Exhibit 99.1**

The table below provides a reconciliation of Segment Adjusted EBITDAR from Operations above to income from operations:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2025** | **2024** |
| Segment Adjusted EBITDAR from Operations<sup>(a)</sup> | $52784 | $36655 | $181356 | $139369 |
| Less: Unallocated corporate expenses | 17483 | 11747 | 60455 | 43587 |
| Less: Depreciation and amortization | 2359 | 1827 | 8538 | 6119 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rent—cost of services | 12997 | 11215 | 48700 | 43029 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other income | 54 | 15 | 422 | 207 |
| Adjustments to Segment EBITDAR from Operations: |  |  |  |  |
| Less: Start-up operations<sup>(b)</sup> | 269 | 209 | 182 | 137 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation expense<sup>(c)</sup> | 2177 | 2425 | 9036 | 8242 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acquisition related costs<sup>(d)</sup> | 1102 | 282 | 6587 | 1278 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Activities associated with transitioning operations<sup>(e)</sup> | 96 | 13 | (880) | (570) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transition services costs<sup>(f)</sup> | 503 |  | 503 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unusual, non-recurring, or redundant charges<sup>(g)</sup> | 12 | 458 | 113 | 1004 |
| Add: Net income attributable to noncontrolling interest | 1738 | 772 | 4186 | 1780 |
| Income from operations | $17470 | $9236 | $51886 | $38116 |

---

(b) Represents results related to start-up operations. This amount excludes rent and depreciation and amortization expense related to such operations.

(c) Share-based compensation expense and related payroll taxes incurred. Share-based compensation expense and related payroll taxes are included in cost of services and general and administrative expense.

(d) Non-capitalizable costs associated with acquisitions and write-offs for amounts in dispute with the prior owners of certain acquired operations.

(e) During 2024 and 2025, an affiliate of the Company held its memory care units in transition and is converting the facility into an assisted living community. We received insurance proceeds related to the property in 2024 and 2025 which were recorded in gain on disposition of property and equipment, net on the consolidated statements of income.

(f) Costs identified as redundant or non-recurring incurred by the Company as a result of the Transition Services Agreement between the Company and UnitedHealth entered into as part of the acquisition agreement. All amounts are included in Cost of services. Fees incurred under the transition services agreement were $3,001 for the year ended December 31, 2025.

(g) Represents unusual, non-recurring, or redundant charges for legal services, implementation costs, integration costs, and consulting fees in general and administrative and cost of services expenses.

------

**Exhibit 99.1**

The tables below reconcile Segment Adjusted EBITDAR from Operations to Segment Adjusted EBITDA from Operations for each reportable segment for the periods presented:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** |
| | **Home Health and Hospice** | **Home Health and Hospice** | **Senior Living** | **Senior Living** |
| | **2025** | **2024** | **2025** | **2024** |
| Segment Adjusted EBITDAR from Operations | $36804 | $23221 | $15980 | $13434 |
| Less: Rent—cost of services | 3107 | 1935 | 9891 | 9280 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rent related to start-up and transitioning operations | (15) | (18) | (52) | (52) |
| Segment Adjusted EBITDA from Operations | $33712 | $21304 | $6141 | $4206 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **Home Health and Hospice** | **Home Health and Hospice** | **Senior Living** | **Senior Living** |
| | **2025** | **2024** | **2025** | **2024** |
| Segment Adjusted EBITDAR from Operations | $120831 | $87709 | $60525 | $51660 |
| Less: Rent—cost of services | 9752 | 7189 | 38949 | 35840 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rent related to start-up and transitioning operations | (56) | (140) | (209) | (393) |
| Segment Adjusted EBITDA from Operations | $111135 | $80660 | $21785 | $16213 |

---

------

**Exhibit 99.1**

***Discussion of Non-GAAP Financial Measures***

EBITDA consists of net income, adjusted for net income attributable to noncontrolling interest ("NCI"), before (a) interest expense, net, (b) provisions for income taxes, and (c) depreciation and amortization. Adjusted EBITDA consists of net income attributable to the Company before (a) interest expense, net (b) provisions for income taxes, (c) depreciation and amortization, (d) results related to start-up operations, including rent and excluding depreciation, interest and income taxes, (e) share-based compensation expense, (f) non-capitalizable acquisition related costs, (g) activities associated with transitioning operations, (h) transition services costs, and (i) unusual, non-recurring or redundant charges. Adjusted EBITDA prior to NCI consists of net income attributable to the Company before (a) interest expense, net (b) provisions for income taxes, (c) depreciation and amortization, (d) results related to start-up operations, (f) non-capitalizable acquisition related costs, (g) activities associated with transitioning operations, (h) transition services costs, (i) unusual, non-recurring or redundant charges, and (j) NCI. Consolidated Adjusted EBITDAR is a valuation measure applicable to current periods only and consists of net income attributable to the Company before (a) interest expense, net, (b) provisions for income taxes, (c) depreciation and amortization, (d) rent-cost of services, (e) results related to start-up operations, excluding rent, depreciation, interest and income taxes, (f) share-based compensation expense, (g) acquisition related costs, (h) activities associated with transitioning operations, (i) transition services costs, and (j) unusual, non-recurring or redundant charges. The company believes that the presentation of EBITDA, adjusted EBITDA, adjusted EBITDA prior to NCI, consolidated adjusted EBITDAR, adjusted net income, and adjusted earnings per share provides important supplemental information to management and investors to evaluate the company's operating performance. The company believes disclosure of adjusted net income, adjusted net income per share, EBITDA, adjusted EBITDA, adjusted EBITDA prior to NCI, and consolidated adjusted EBITDAR has economic substance because the excluded revenues and expenses are infrequent in nature and are variable in nature, or do not represent current revenues or cash expenditures. A material limitation associated with the use of these measures as compared to the GAAP measures of net income and diluted earnings per share is that they may not be comparable with the calculation of net income and diluted earnings per share for other companies in the company's industry. These non-GAAP financial measures should not be relied upon to the exclusion of GAAP financial measures. For further information regarding why the company believes that this non-GAAP measure provides useful information to investors, the specific manner in which management uses this measure, and some of the limitations associated with the use of this measure, please refer to the company's periodic filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Report on Form 10-Q. The company's periodic filings are available on the SEC's website at www.sec.gov or under the "Financial Information" link of the Investor Relations section on Pennant's website at http://www.pennantgroup.com.

<br>